|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Rochester, MN 55901, US
|
|
At Vyriad, we are developing the next generation of targeted cancer therapies. Oncolytic virotherapies use engineered viruses to selectively attack cancer cells, igniting robust immune responses and preventing cancer recurrence. We believe our viral-based therapies have tremendous potential to improve the lives of patients, inspire hope, and change the way cancer is treated.
Our Phase 1-2 Clinical Studies include:
Non-small cell lung cancer
Squamous cell carcinoma of the head and neck
Metastatic colorectal cancer
Bladder cancer
Other cancer types
We are testing our oncolytic viruses as monotherapies or in combination with immuno-oncology drugs. Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, Merck KGaA/Pfizer, and other leading research and medical institutions.
|
Vyriad Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Vyriad email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Vyriad customer service number call here 1-507-289-0944. To contact Vyriad customer service number in your country click here to find.
Stephen Russell is the CEO of Vyriad. To contact Stephen Russell email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.